-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …
You May Also Like
This Fun Utility Vehicle (FUV) Makes You Wish You Had One or Two or a Fleet
A Staple in Automotive Accessories Could Become Essential During Natural Disasters
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
-
Digital Transformation Of Emerging Markets Could Mean Continued Opportunity For Newly NASDAQ Listed Japanese Company
Previously published on Benzinga HeartCore Enterprises Inc. (NASDAQ: HTCR) is a software-as-a-service (SaaS) solutions provider and leading development company in the enterprise business sector. In February, the company was uplisted to the Nasdaq Stock Exchange and rang the opening bell. Last June, Founder and CEO Sumitaka Kanno was honored with the Top 100 Tech Innovators & Influencers Award at InterCon Las Vegas for his significant and tangible contributions to the world of technology. HeartCore already held the largest market share in Japan for six straight years. It All Started With A Vision Founded in 2009, HeartCore (formerly XyXon Inc.) entered the market with its cornerstone HeartCore CMS rich content management…
-
CXM Software Creator Just Uplisted Last Month — Here’s What You May Want To Know
Previously Published on Benzinga HeartCore Enterprises Inc. (NASDAQ: HTCR) is a software-as-a-service (SaaS) solutions company that says it believes in making its customers and employees happy. The focus of many of its products is based on knowing the customer. When listing the three steps for successful digital marketing, HeartCore states that it emphasizes the need to know your customers, support them and keep them engaged. Who Is HeartCore Enterprises, Anyway? Headquartered in Tokyo, Japan, with offices in San Francisco, HeartCore Enterprises is a software development company in the enterprise business sector. The company booked $11 million in revenue for the 12 months ending on Sept. 30. On Feb. 9, it announced a $15 million…
-
Vision in Sight — Vuzix Outlines Ultra-Sleek Lineup of Smart Glasses, CES 2022 Presence, and Partnerships
Previously Published to Benzinga It’s a new year, and 2022 may just become the Year of the Meta with virtual reality (VR), augmented reality (AR), and extended reality (XR) around every corner. Vuzix Corp. (NASDAQ: VUZI) is arguably no exception, leaving 2021 with a bang and entering the new year fresh-faced and making moves. The company is a leading supplier of smart glasses and AR technologies, developing innovative products primarily focused on enterprise markets. This includes personal displays and wearable computing devices triggered by touchpad, voice, and Bluetooth inputs. In addition, it offers users a portable, high-quality viewing experience, shared view video streaming, and dynamic solutions for mobility purposes. That means…
-
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward. According to Statera, preclinical testing is underway in the screening of second-generation immune therapies using the ImQuest platform for the rapid and accurate assessment of various diseases and how the overall makeup and composition of these diseases interact. The company will look more closely…
